Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 8, 2013, Pages 618-623

  Brindisi, M C ^a,b,c   Duvillard, L ^a,b,d   Monier, S ^a   Verges B ^a,b,c   Persegol L ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HÔPITAL DU BOCAGE   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetes mellitus; Glycation; HDL; Oxidized LDL; Vasorelaxation

Indexed keywords

ACETYLCHOLINE; APOLIPOPROTEIN A1; FRUCTOSAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NORADRENALIN;

ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; ENDOTHELIUM; FEMALE; GLYCATION; HUMAN; MALE; PRIORITY JOURNAL; VASCULAR RING; VASODILATATION;

DIABETES MELLITUS; GLYCATION; HDL; OXIDIZED LDL; VASORELAXATION;

ANIMALS; AORTA; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSYLATION; HEALTHY VOLUNTEERS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MODELS, ANIMAL; RABBITS; VASODILATION;

EID: 84887756837     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2434     Document Type: Article

References (33)

1. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 2003; 46: 760-765.
2. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
3. Vergès B. Lipid disorders in type 1 diabetes. Diabetes Metab 2009; 35: 353-360.
4. Vergès B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009; 23: 681-685.
5. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003; 278: 9142-9.
6. Nofer JR, van der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113: 569-581.
7. Perségol L, Foissac M, Lagrost L, et al. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007; 50: 2384-2387.
8. Perségol L, Vergès B, Foissac M, et al. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2006; 49: 1380-1386.
9. Nobecourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005; 48: 529-538.
10. Deckert V, Perségol L, Viens L, et al. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 1997; 95: 723-731.
11. Fournier N, Myara I, Atger V, Moatti N. Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high-density lipoproteins (HDL). Clin Chim Acta 1995; 234: 47-61.
12. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes 1990; 39: 1257-63.
13. Calvo C, Ponsin G, Berthezene F. Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. Diabete Metab 1988; 14: 264-9.
14. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344(Pt 1): 109-16.
15. Beisswenger PJ, Howell SK, Nelson RG, et al. Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 2003; 31(Pt 6): 1358-63.
16. Younis NN, Soran H, Charlton-Menys V, et al. High-density lipoprotein impedes glycation of low-density lipoprotein. Diab Vasc Dis Res 2013; 10(2): 152-60.
17. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009; 120: 1266-1286.
18. Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 1996; 7: 274-80.
19. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 1999; 274: 32512-32519.
20. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45: 993-1007.
21. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273: 6088-6095.
22. Panzenbock U, Stocker R. Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim Biophys Acta 2005; 1703: 171-181.
23. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.
24. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11: 155-161.
25. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000; 275: 11278-11283.
26. Kimura T, Tomura H, Mogi C, et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006; 281: 37457-37467.
27. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7: 853-857.
28. Terasaka N, Westerterp M, Koetsveld J, et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol 2010; 30: 2219-25.
29. Nobecourt E, Tabet F, Lambert G, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein a-I. Arterioscler Thromb Vasc Biol 2010; 30: 766-772.
30. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-320.
31. Ferretti G, Baccheti T, Marchionni C, Calderetti L, Curatola T. Effect of glycation of high-density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38: 163-169.
32. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991; 40: 377-384.
33. Calvo C, Talussot C, Ponsin G, Berthezène F. Non enzymatic glycation of apolipoprotein A1. Effects on its self-association and lipid binding properties. Biochem Biophys Res Commun 1988; 153: 1060-1067.